Trial Profile
A Phase 2, Randomized, Open-Label, Dose Titration, Efficacy and Safety Study of FG-4592 (Roxadustat) in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors FibroGen
- 20 Apr 2016 Results published in Clinical Journal of the American Society of Nephrology, according to a FibroGen media release.
- 20 Apr 2016 Results published in a FibroGen media release.
- 18 Sep 2014 New trial record